Posted by Michael Wonder on 22 Sep 2023
89bio announces US FDA has granted breakthrough therapy designation for pegozafermin in non-alcoholic steatohepatitis
21 September 2023 - Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin.
89bio today announced that the US FDA granted breakthrough therapy designation to pegozafermin in patients with nonalcoholic steatohepatitis.
